Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals OCF Margin

The Operating Cash Flow Margin of Arrowhead Pharmaceuticals (ARWR) as of Nov 2, 2026 is 21.65 %. In the previous year, Operating Cash Flow Margin was -13,034.38 % — a change of -100.17% (higher).

OCF Margin

21.65 %

YoY

-100.17%

Last updated:

Operating Cash Flow Margin of Arrowhead Pharmaceuticals is 2025 21.65 % . Operating Cash Flow Margin of Arrowhead Pharmaceuticals was 2024 -13,034.38 % . It decreases by -100.17% higher compared to the previous year.

The Arrowhead Pharmaceuticals OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-292.54 USD
Jan 1, 2019
102.51 USD
Jan 1, 2020
-108.87 USD
Jan 1, 2021
123.88 USD
Jan 1, 2022
-55.97 USD
Jan 1, 2023
-63.93 USD
Jan 1, 2024
-13,034.38 USD
Jan 1, 2025
21.65 USD
The Arrowhead Pharmaceuticals OCF Margin history
YEAROCF MarginYoY
21.65 %-100.17%
-13,034.38 %+20,290.10%
-63.93 %+14.22%
-55.97 %-145.18%
123.88 %-213.78%
-108.87 %-206.21%
102.51 %-135.04%
-292.54 %+283.82%
-76.22 %-99.81%
-40,691.13 %+136.56%
-17,200.95 %-15.01%
-20,237.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Arrowhead Pharmaceuticals Stock analysis

What does Arrowhead Pharmaceuticals do? Arrowhead Pharmaceuticals Inc is a biotechnology company that develops and commercializes RNA-based therapeutics. The company is headquartered in Pasadena, California and was founded in 2007. Arrowhead's history began when a group of scientists at the University of Texas came together to work on the development of RNA-based therapeutics. In 2007, Arrowhead was established and the company's patented TRiM™ (Targeted RNAi Molecules) technology was developed to specifically overcome barriers in RNAi-based therapeutics. The company is divided into several divisions, including Hepatitis B, cardiovascular, metabolic disorders, and oncology. Arrowhead has developed a range of RNAi-based investigational products, including ARC-520, which is being developed for the treatment of Hepatitis B and is currently in clinical trials. ARC-520 is designed to inhibit the formation and release of viral particles in liver cells, thereby halting the progression of the disease. Arrowhead has also developed products for the treatment of life-threatening diseases such as Alpha-1 Antitrypsin Deficiency (AAT) and hypertriglyceridemic pancreatitis (HTG). The treatments offered by Arrowhead aim to utilize RNA in disease treatment where other methods have failed. Arrowhead Pharmaceuticals Inc's business model is based on the discovery, development, and commercialization of RNAi-based therapeutics. The company collaborates with partners to accelerate the development and commercialization of its products. Arrowhead has a strategic partnership with Johnson & Johnson Pharmaceuticals Research & Development, LLC. Arrowhead Pharmaceuticals Inc is listed on the NASDAQ stock exchange under the ticker symbol ARWR. The company employs approximately 150 employees, including scientists, researchers, and specialists specialized in RNA biology. Recently, Arrowhead Pharmaceuticals Inc partnered with Takeda Pharmaceutical Co. Ltd. to develop RNAi-based therapeutics. This partnership aims to accelerate the development of RNAi-based therapeutics and optimize the company's potential in the field of RNA biology. In summary, Arrowhead Pharmaceuticals is a biotechnology company specializing in RNA biology. The company has developed a patented TRiM™ technology that specifically overcomes barriers in disease therapy with RNAi-based therapeutics. Arrowhead has developed several products for the treatment of life-threatening diseases and collaborates with partners to accelerate the development of its products and optimize commercialization. Arrowhead Pharmaceuticals Inc is an innovative player in the biotechnology field and strives to improve and revolutionize the common practice of RNAi-based therapeutics. Arrowhead Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arrowhead Pharmaceuticals stock

Operating Cash Flow Margin of Arrowhead Pharmaceuticals is 21.65 % in 2025.

Operating Cash Flow Margin of Arrowhead Pharmaceuticals changed from -13,034.38 % to 21.65 %, representing a -100.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Arrowhead Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Arrowhead Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Arrowhead Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Arrowhead Pharmaceuticals